Lantheus Holdings, Inc. which can be found using ticker (LNTH) have now 11 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $175.00 and $125.00 and has a mean share price target at $145.36. (at the time of writing). Now with the previous closing price of $106.36 this would indicate that there is a potential upside of 36.7%. Also worth taking note is the 50 day moving average now sits at $101.66 and the 200 day moving average is $75.17. The total market capitalization for the company now stands at 7.31B. The stock price is currently at: $105.34 USD
The potential market cap would be $9,995,644,506 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 17.33, revenue per share of $20.91 and a 17.41% return on assets.
Lantheus Holdings, Inc. is an integrated provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight and follow serious medical conditions. The Company’s products include precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Its precision diagnostic products assist healthcare professionals (HCPs) Find and Follow diseases, with a focus on cardiology. Its radiopharmaceutical oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Its strategic partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes the Company’s license of RELISTOR to Bausch Health Companies, Inc. (Bausch). Its commercial products are used by oncologists, urologists, nuclear medicine physicians, cardiologists, sonographers, technologists, radiologists, and internal medicine physicians working in a variety of clinical settings.
